Exabis Library
Welcome to the e-CCO Library!
P384: Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P385 A mucosal marker predicting tofacitinib induced an endoscopic response in ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P385: Assessment of long-term outcomes of patients with ulcerative colitis and mucosal healing under different therapies: Is all mucosal healing the same?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P385: Colectomy-free survival and factors associated with it in children with ulcerative colitis managed in a tertiary IBD centre in the UK
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P385: Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P385: Results of a teleconsultation campaign for Inflammatory Bowel Disease (IBD) patients to check their treatment adherence and assess their level of anxiety during the first COVID-19 lockdown
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P385: Risk-benefit assessment of IBD drugs: a physicians and patients survey
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P385: Tailoring induction treatment for children with Crohn’s disease.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P385: TREM1, the first anti-TNF specific biomarker guiding therapeutic decision
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P386: A target 6-thioguanine nucleotide ≥125 is associated with a higher rate and longer durability of response in infliximab–thiopurine combination therapy: a retrospective study in Crohn's disease patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P386: Anti-TNF alpha as induction and maintenance therapy in ulcerative colitis patients in the BioColitis Registry in Germany
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P386: Association of Infliximab trough levels and perianal disease activity in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P386: Clinical presentation, management, and evolution of lymphomas in patients with Inflammatory Bowel Disease: an ENEIDA registry study.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P386: Methotrexate use in combination with anti-TNFα agents in IBD: A tertiary centre experience
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P386: Predictive models for assessing the response to ustekinumab in Crohn’s disease patients
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P386: Two year follow up of children with Inflammatory Bowel Disease (IBD) treated with vedolizumab and ustekinumab
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P387 Real-world clinical outcomes of biologic-naïve non-complicated Crohn’s disease patients treated with vedolizumab: Results from the EVOLVE study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P387: Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P387: Different rate of transmural remission between first and second line of biologic treatment in Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM